본문으로 건너뛰기
← 뒤로

Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2.

1/5 보강
Blood and lymphatic cancer : targets and therapy 2026 Vol.16() p. 559759 OA
Retraction 확인
출처

Espinoza-Gutarra MR, Jarrett BA, Wang X, Afghahi A, Bae S

📝 환자 설명용 한 줄

Acute Myeloid Leukemia (AML) is a common hematologic neoplasm in adults and usually carries a grim prognosis.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Espinoza-Gutarra MR, Jarrett BA, et al. (2026). Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2.. Blood and lymphatic cancer : targets and therapy, 16, 559759. https://doi.org/10.2147/BLCTT.S559759
MLA Espinoza-Gutarra MR, et al.. "Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2.." Blood and lymphatic cancer : targets and therapy, vol. 16, 2026, pp. 559759.
PMID 41847630 ↗

Abstract

Acute Myeloid Leukemia (AML) is a common hematologic neoplasm in adults and usually carries a grim prognosis. Therapy has traditionally consisted of intensive chemotherapy; however, recent advances have led to the development of Tyrosine Kinase Inhibitors (TKI) as Targeted Therapies for subtypes carrying certain mutations. While the clinical impact of these therapies has been well described, there have been no studies looking at clinical disparities among different racial/ethnic groups receiving these therapies. We leveraged an EHR-derived database to evaluate real-world outcomes in patients receiving TKIs for AML. Our study found no significant differences between real-world Event Free Survival (rwEFS) and real world Overall Survival (rwOS) across patients of different racial/ethnic groups, this suggests that when patients have access to targeted therapy outcomes across different racial/ethnic groups become more equitable.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기